Literature DB >> 18379939

Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma.

H Nida Sen1, Chi-Chao Chan, Gordon Byrnes, Robert N Fariss, Robert B Nussenblatt, Ronald R Buggage.   

Abstract

PURPOSE: To describe the clinical course of a patient with multiple recurrences of primary intraocular lymphoma (PIOL).
DESIGN: Interventional case report,
METHODS: Retrospective chart review.
RESULTS: A 57-year-old female treated with multiple intravitreal methotrexate injections became refractory to intravitreal methotrexate after a year. Lymphoma cells evaluated using immunocytochemistry and confocal microscopy showed aberrant multidrug resistance-related protein (MRP) and decreased reduced folate carrier (RFC) and folate binding protein (FBP) expression compared to PIOL cells from another patient clinically responsive to methotrexate.
CONCLUSIONS: This case suggests that alterations in the transport of methotrexate across the cell membrane might contribute to resistance following repeated intravitreal injections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379939      PMCID: PMC2561282          DOI: 10.1080/09273940801899764

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  9 in total

1.  Primary intraocular lymphoma diagnosed by fine needle aspiration biopsy of a subretinal lesion.

Authors:  G A Levy-Clarke; G A Byrnes; R R Buggage; D F Shen; A C Filie; R C Caruso; R B Nussenblatt; C C Chan
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells.

Authors:  Yehuda G Assaraf; Lilah Rothem; Jan Hendrik Hooijberg; Michal Stark; Ilan Ifergan; Ietje Kathmann; Ben A C Dijkmans; Godefridus J Peters; Gerrit Jansen
Journal:  J Biol Chem       Date:  2002-12-16       Impact factor: 5.157

3.  Epidemiology of primary CNS lymphoma.

Authors:  M Schabet
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 4.  Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.

Authors:  Shrikanta Chattopadhyay; Richard G Moran; I David Goldman
Journal:  Mol Cancer Ther       Date:  2007-02       Impact factor: 6.261

Review 5.  Molecular basis of antifolate resistance.

Authors:  Yehuda G Assaraf
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

6.  Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.

Authors:  Justine R Smith; James T Rosenbaum; David J Wilson; Nancy D Doolittle; Tali Siegal; Edward A Neuwelt; Jacob Pe'er
Journal:  Ophthalmology       Date:  2002-09       Impact factor: 12.079

Review 7.  Intraocular lymphoma.

Authors:  Chi-Chao Chan; Ronald R Buggage; Robert B Nussenblatt
Journal:  Curr Opin Ophthalmol       Date:  2002-12       Impact factor: 3.761

8.  IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma.

Authors:  Nathalie Cassoux; Alain Giron; Bahram Bodaghi; Thi H C Tran; Sylvie Baudet; Fréderic Davy; Chi C Chan; Phuc Lehoang; Hélène Merle-Béral
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

Review 9.  Intraocular lymphoma: update on diagnosis and management.

Authors:  Chi-Chao Chan; Dana J Wallace
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

  9 in total
  11 in total

1.  IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas.

Authors:  Hema L Ramkumar; De Fen Shen; Jingsheng Tuo; Rita M Braziel; Sarah E Coupland; Justine R Smith; Chi-Chao Chan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-25       Impact factor: 3.117

Review 2.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 3.  Intraocular lymphoma.

Authors:  Li-Juan Tang; Chang-Lin Gu; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

4.  The future of primary intraocular lymphoma (retinal lymphoma).

Authors:  Chi-Chao Chan; Sylvain Fisson; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

5.  Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region.

Authors:  Aseef H Ahmed; C Stephen Foster; Carol L Shields
Journal:  JAMA Ophthalmol       Date:  2017-10-01       Impact factor: 7.389

Review 6.  Primary intraocular lymphoma: diagnosis and differential diagnosis.

Authors:  H Nida Sen; Bahram Bodaghi; Phuc Le Hoang; Robert Nussenblatt
Journal:  Ocul Immunol Inflamm       Date:  2009 May-Jun       Impact factor: 3.070

7.  Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.

Authors:  Yujuan Wang; Dik S Cheung; Chi-Chao Chan
Journal:  Ann Eye Sci       Date:  2017-07-01

Review 8.  Intraocular lymphoma: a clinical perspective.

Authors:  J L Davis
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

9.  Clinical sign and symptom of primary vitreoretinal lymphoma short-time after retinal reattachment surgery: a case report.

Authors:  Marjan Imani Fooladi; Abdulrahim Amini; Hamid Riazi-Esfahani; Nazanin Ebrahimiadib; Mohammadkarim Johari; Fariba Ghassemi
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-02-05

10.  Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma.

Authors:  Harish Raja; Melissa R Snyder; Patrick B Johnston; Brian P O'Neill; Juline N Caraballo; Joseph G Balsanek; Brian E Peters; Paul A Decker; Jose S Pulido
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.